Robeco Institutional Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Robeco Institutional Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,329	Closed	-$214K	–	967
2022 Q1	$214K	Hold	4,329	–	–	﹤0.01%	841
2021 Q4	$220K	Hold	4,329	–	–	﹤0.01%	836
2021 Q3	$242K	Hold	4,329	–	–	﹤0.01%	833
2021 Q2	$185K	Hold	4,329	–	–	﹤0.01%	887
2021 Q1	$180K	Hold	4,329	–	–	﹤0.01%	884
2020 Q4	$202K	Hold	4,329	–	–	﹤0.01%	853
2020 Q3	$184K	Hold	4,329	–	–	﹤0.01%	849
2020 Q2	$208K	Hold	4,329	–	–	﹤0.01%	886
2020 Q1	$199K	Hold	4,329	–	–	﹤0.01%	888
2019 Q4	$260K	Sell	4,329 -2,791	-39%	-$166K	﹤0.01%	883
2019 Q3	$403K	Buy	7,120 +4,870	+216%	+$274K	﹤0.01%	855
2019 Q2	$126K	Hold	2,250	–	–	﹤0.01%	929
2019 Q1	$114K	Hold	2,250	–	–	﹤0.01%	925
2018 Q4	$90K	Hold	2,250	–	–	﹤0.01%	925
2018 Q3	$156K	Buy	+2,250	New	+$171K	﹤0.01%	924

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Robeco Institutional Asset Management's EGRX Position: Q2 2022 in Review

Robeco Institutional Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2022, closing a stake of 4,329 shares — an estimated $214K sold.

Robeco Institutional Asset Management first reported a position in EGRX in Q3 2018 and held it in 15 quarters. The position peaked at $403K in Q3 2019. 163 funds tracked by Wall St. Rank hold EGRX as of Q2 2022.

Robeco Institutional Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Robeco Institutional Asset Management sold 4,329 Eagle Pharmaceuticals, Inc. shares in Q2 2022, an estimated $214K.
Robeco Institutional Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 15 quarters.
Robeco Institutional Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $403K in Q3 2019.
163 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2022.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2022, filed 27 Jul 2022.